home / stock / raonf / raonf news
(NewsDirect) Race Oncology Ltd (ASX:RAC, OTC:RAONF) CEO Dr Daniel Tillett joins Proactive’s Jonathan Jackson to discuss promising preclinical findings. Research indicated that combining bisantrene with decitabine greatly enhances the destruction of cancer cells across a wide variety of...
(NewsDirect) Race Oncology Ltd (ASX:RAC) CEO Daniel Tillett joins Jonathan Jackson in the Proactive studio to provide an update on the company’s movements over the last few months. Just recently, Race received a $4 million R&D tax incentive tto accelerate clinical development of bi...
(NewsDirect) Race Oncology Ltd (ASX:RAC) executive director Pete Smith speaks with Proactive alongside the company’s recently appointed CEO - 25-year veteran of the biotech space, Dr Daniel Tillett. In this pivotal role, Dr Tillett will work closely with Dr Smith to steer the company's...
(NewsDirect) Race Oncology Ltd (ASX:RAC) executive director Dr Pete Smith discusses with Proactive impressive Phase 2 clinical trial results from its Acute Myeloid Leukaemia (AML) clinical trial. The interim clinical results are from an ongoing investigator-initiated Phase 2 trial of bisantre...
(NewsDirect) Race Oncology Ltd (ASX:RAC) executive director Dr Pete Smith speaks with Proactive soon after announcing the company has initiated the toxicology and safety pharmacology studies required to support human clinical trials of its flagship bisantrene formulation for peripheral infusi...
(NewsDirect) Race Oncology Ltd (ASX:RAC) CEO and managing director Damian Clarke-Bruce speaks with Proactive soon after launching a new corporate strategy focused on maximising bisantrene’s anti-cancer and cardio-protective potential. The company’s lead clinical focus will b...
(NewsDirect) Race Oncology CEO Damian Clark-Bruce joined Steve Darling from Proactive to share significant news about the company's recent agreements and partnerships. Firstly, Race Oncology has signed an agreement with Ardena Holding, a global contract development and manufacturing o...
(NewsDirect) Race Oncology Ltd (ASX:RAC) CEO Damian Clarke-Bruce tells Proactive that they will shortly start assessing the cardiovascular-protective properties of Zantrene® (bisantrene) treatment in the observational stage of a Phase 1/2b clinical trial in breast cancer patients treated...
News, Short Squeeze, Breakout and More Instantly...
Race Oncology Company Name:
RAONF Stock Symbol:
OTCMKTS Market:
(NewsDirect) Race Oncology Ltd (ASX:RAC, OTC:RAONF) CEO Dr Daniel Tillett joins Proactive’s Jonathan Jackson to discuss promising preclinical findings. Research indicated that combining bisantrene with decitabine greatly enhances the destruction of cancer cells across a wide variety of...
(NewsDirect) Race Oncology Ltd (ASX:RAC) CEO Daniel Tillett joins Jonathan Jackson in the Proactive studio to provide an update on the company’s movements over the last few months. Just recently, Race received a $4 million R&D tax incentive tto accelerate clinical development of bi...
(NewsDirect) Race Oncology Ltd (ASX:RAC) executive director Pete Smith speaks with Proactive alongside the company’s recently appointed CEO - 25-year veteran of the biotech space, Dr Daniel Tillett. In this pivotal role, Dr Tillett will work closely with Dr Smith to steer the company's...